SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Study aims to identify clinical subtypes in patients with schizophrenia October 29, 2024 Study unlocks the mystery of neonatal neutropenia in newborns March 17, 2024 Study reveals skin tone bias in photoacoustic imaging for breast cancer detection November 16, 2024